Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom.

Perry LT, Bhasale A, Fabbri A, Lexchin J, Puil L, Joarder M, Mintzes B.

JAMA Intern Med. 2019 Apr 29. doi: 10.1001/jamainternmed.2019.0294. [Epub ahead of print] No abstract available.

PMID:
31033999
2.

Secret safety warnings on medicines: A case study of information access requests.

Torka M, Mintzes B, Bhasale A, Fabbri A, Perry L, Lexchin J.

Pharmacoepidemiol Drug Saf. 2019 Apr;28(4):551-555. doi: 10.1002/pds.4762. Epub 2019 Mar 6.

PMID:
30840349
3.

Pharmaceutical Industry Funding of Health Consumer Groups in Australia: A Cross-sectional Analysis.

Fabbri A, Swandari S, Lau E, Vitry A, Mintzes B.

Int J Health Serv. 2019 Apr;49(2):273-293. doi: 10.1177/0020731418823376. Epub 2019 Jan 15.

PMID:
30646806
4.

The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures.

Bero L, Chartres N, Diong J, Fabbri A, Ghersi D, Lam J, Lau A, McDonald S, Mintzes B, Sutton P, Turton JL, Woodruff TJ.

Syst Rev. 2018 Dec 21;7(1):242. doi: 10.1186/s13643-018-0915-2.

5.

Disease awareness campaigns in printed and online media in Latvia: cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards.

Leonardo Alves T, Poplavska E, Mezinska S, Salmane-Kulikovska I, Andersone L, Mantel-Teeuwisse AK, Mintzes B.

BMC Public Health. 2018 Nov 28;18(1):1322. doi: 10.1186/s12889-018-6202-2.

6.

Industry sponsorship and research outcome: systematic review with meta-analysis.

Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L.

Intensive Care Med. 2018 Oct;44(10):1603-1612. doi: 10.1007/s00134-018-5293-7. Epub 2018 Aug 21. Review.

PMID:
30132025
7.

How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study.

Lau E, Fabbri A, Mintzes B.

Aust Health Rev. 2018 Jul 19. doi: 10.1071/AH17288. [Epub ahead of print]

PMID:
30021681
8.

Mental Health Messages in Prominent Mental Health Apps.

Parker L, Bero L, Gillies D, Raven M, Mintzes B, Jureidini J, Grundy Q.

Ann Fam Med. 2018 Jul;16(4):338-342. doi: 10.1370/afm.2260.

9.

Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.

Fabbri A, Santos A, Mezinska S, Mulinari S, Mintzes B.

Int J Health Policy Manag. 2018 Mar 14;7(6):504-509. doi: 10.15171/ijhpm.2018.20.

10.

Medicines Information and the Regulation of the Promotion of Pharmaceuticals.

Leonardo Alves T, Lexchin J, Mintzes B.

Sci Eng Ethics. 2018 May 2. doi: 10.1007/s11948-018-0041-5. [Epub ahead of print]

PMID:
29721844
11.

The rise of ambiguous competing interest declarations.

Mintzes B, Grundy Q.

BMJ. 2018 Apr 10;361:k1464. doi: 10.1136/bmj.k1464. No abstract available.

PMID:
29636334
12.

The marketing of testosterone treatments for age-related low testosterone or 'Low T'.

Mintzes B.

Curr Opin Endocrinol Diabetes Obes. 2018 Jun;25(3):224-230. doi: 10.1097/MED.0000000000000412. Review.

PMID:
29570470
13.

Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over-active bladder syndrome? An Australian cohort study.

Mintzes B, Swandari S, Fabbri A, Grundy Q, Moynihan R, Bero L.

BMJ Open. 2018 Feb 13;8(2):e019027. doi: 10.1136/bmjopen-2017-019027.

14.

Reconciling a "pleasant exchange" with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care.

Reynolds E, Guénette L, Lexchin J, Cassels A, Wilkes MS, Durrieu G, Beaulieu MD, Mintzes B.

Health Policy. 2018 Mar;122(3):250-255. doi: 10.1016/j.healthpol.2018.01.010. Epub 2018 Feb 1.

PMID:
29395543
15.

Mental health care and suicide in pregnancy and postpartum.

Mintzes B.

CMAJ. 2017 Dec 4;189(48):E1498. doi: 10.1503/cmaj.733429. No abstract available.

16.

A health app developer's guide to law and policy: a multi-sector policy analysis.

Parker L, Karliychuk T, Gillies D, Mintzes B, Raven M, Grundy Q.

BMC Med Inform Decis Mak. 2017 Oct 2;17(1):141. doi: 10.1186/s12911-017-0535-0.

17.

Response to "use of domperidone and risk of ventricular arrhythmia in the postpartum period: Getting to the heart of the matter".

Smolina K, Morgan S, Mintzes B, Hanley G, Oberlander T.

Pharmacoepidemiol Drug Saf. 2017 Jul;26(7):865-866. doi: 10.1002/pds.4229. No abstract available.

PMID:
28671317
18.

A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia.

Fabbri A, Grundy Q, Mintzes B, Swandari S, Moynihan R, Walkom E, Bero LA.

BMJ Open. 2017 Jun 30;7(6):e016701. doi: 10.1136/bmjopen-2017-016701.

19.

Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?

Habibi R, Lexchin J, Mintzes B, Holbrook A.

Br J Clin Pharmacol. 2017 Nov;83(11):2549-2556. doi: 10.1111/bcp.13360. Epub 2017 Aug 19.

20.

Regulating Information or Allowing Deception? Pharmaceutical Sales Visits in Canada, France, and the United States.

Habibi R, Guénette L, Lexchin J, Reynolds E, Wiktorowicz M, Mintzes B.

J Law Med Ethics. 2016 Dec;44(4):602-613. doi: 10.1177/1073110516684803.

PMID:
28661249
21.

Industry sponsorship and research outcome.

Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L.

Cochrane Database Syst Rev. 2017 Feb 16;2:MR000033. doi: 10.1002/14651858.MR000033.pub3. Review.

PMID:
28207928
22.

Conflict of Interest Policies at French Medical Schools: Starting from the Bottom.

Scheffer P, Guy-Coichard C, Outh-Gauer D, Calet-Froissart Z, Boursier M, Mintzes B, Borde JS.

PLoS One. 2017 Jan 9;12(1):e0168258. doi: 10.1371/journal.pone.0168258. eCollection 2017.

23.

The Inclusion of Nurses in Pharmaceutical Industry-Sponsored Events: Guess Who Is Also Coming to Dinner?

Grundy Q, Fabbri A, Mintzes B, Swandari S, Bero L.

JAMA Intern Med. 2016 Nov 1;176(11):1718-1720. doi: 10.1001/jamainternmed.2016.5276. No abstract available.

PMID:
27617386
24.

A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.

Morgan SG, Gagnon MA, Mintzes B, Lexchin J.

Healthc Policy. 2016 Aug;12(1):18-36.

25.

In Reply.

Hanley GE, Mintzes B.

Obstet Gynecol. 2016 Aug;128(2):406. doi: 10.1097/AOG.0000000000001542. No abstract available.

PMID:
27454714
26.

The association between domperidone and ventricular arrhythmia in the postpartum period.

Smolina K, Mintzes B, Hanley GE, Oberlander TF, Morgan SG.

Pharmacoepidemiol Drug Saf. 2016 Oct;25(10):1210-1214. doi: 10.1002/pds.4035. Epub 2016 Jun 14.

PMID:
27296864
27.

Postpartum domperidone use in British Columbia: a retrospective cohort study.

Smolina K, Morgan SG, Hanley GE, Oberlander TF, Mintzes B.

CMAJ Open. 2016 Jan 12;4(1):E13-9. doi: 10.9778/cmajo.20150067. eCollection 2016 Jan-Mar.

29.

Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults.

Morgan SG, Weymann D, Pratt B, Smolina K, Gladstone EJ, Raymond C, Mintzes B.

Age Ageing. 2016 Jul;45(4):535-42. doi: 10.1093/ageing/afw074. Epub 2016 May 5.

30.

Access to new cancer medicines in Australia: dispelling the myths and informing a public debate.

Vitry A, Mintzes B, Lipworth W.

J Pharm Policy Pract. 2016 Apr 7;9:13. doi: 10.1186/s40545-016-0062-x. eCollection 2016.

31.

Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation.

Cosgrove L, Vannoy S, Mintzes B, Shaughnessy AF.

Account Res. 2016;23(5):257-79. doi: 10.1080/08989621.2016.1153971.

PMID:
26890488
32.

Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy.

Hanley GE, Smolina K, Mintzes B, Oberlander TF, Morgan SG.

Obstet Gynecol. 2016 Mar;127(3):553-61. doi: 10.1097/AOG.0000000000001200.

PMID:
26855096
33.

Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect.

Mintzes B, Lexchin J, Quintano AS.

Br Med Bull. 2015;116:43-53. doi: 10.1093/bmb/ldv042. Epub 2015 Oct 21. Review.

PMID:
26493102
34.

Authors' reply to Lee and colleagues.

Järvinen T, Michaëlsson K, Jokihaara J, Collins GS, Perry TL, Mintzes B, Musini V, Erviti J, Gorricho J, Wright JM, Sievänen H.

BMJ. 2015 Jul 14;351:h3737. doi: 10.1136/bmj.h3737. No abstract available.

PMID:
26174986
35.

When drugs don't make it to market.

Mintzes B.

BMJ. 2015 Jun 9;350:h2852. doi: 10.1136/bmj.h2852. No abstract available.

PMID:
26060187
36.

Overdiagnosis of bone fragility in the quest to prevent hip fracture.

Järvinen TL, Michaëlsson K, Jokihaara J, Collins GS, Perry TL, Mintzes B, Musini V, Erviti J, Gorricho J, Wright JM, Sievänen H.

BMJ. 2015 May 26;350:h2088. doi: 10.1136/bmj.h2088. No abstract available.

PMID:
26013536
37.

Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002-2011: A Population-Based Cohort Study.

Smolina K, Hanley GE, Mintzes B, Oberlander TF, Morgan S.

PLoS One. 2015 May 26;10(5):e0128312. doi: 10.1371/journal.pone.0128312. eCollection 2015.

38.

New oral anticoagulants.

Perry TL, Wright JM, Mintzes B, O'Sullivan C, Tejani AM.

CMAJ. 2015 May 19;187(8):603. doi: 10.1503/cmaj.1150037. No abstract available.

39.

A compromise too far: a review of Canadian cases of direct-to-consumer advertising regulation.

Lexchin J, Mintzes B.

Int J Risk Saf Med. 2014;26(4):213-25. doi: 10.3233/JRS-140635. Review.

PMID:
25420763
40.

Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance.

Hanley GE, Mintzes B.

BMC Pregnancy Childbirth. 2014 Jul 22;14:242. doi: 10.1186/1471-2393-14-242.

41.

Regulating prescription drugs for patient safety: does Bill C-17 go far enough?

Herder M, Gibson E, Graham J, Lexchin J, Mintzes B.

CMAJ. 2014 May 13;186(8):E287-92. doi: 10.1503/cmaj.131850. Epub 2014 Mar 10. Review. No abstract available.

42.

A leap of faith in antidepressant treatment?

Mintzes B.

JAMA Psychiatry. 2013 Dec;70(12):1373. doi: 10.1001/jamapsychiatry.2013.2114. No abstract available.

PMID:
24306812
43.

Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.

Nguyen CT, MacEntee MI, Mintzes B, Perry TL.

Drugs Aging. 2014 Jan;31(1):55-65. doi: 10.1007/s40266-013-0141-5.

PMID:
24293180
44.

A Systematic Review of Intravitreal Bevacizumab for the Treatment of Diabetic Macular Edema [Internet].

Fortin P, Mintzes B, Innes M.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2012 May.

45.

Pharmaceutical sales representatives and patient safety.

Mintzes B, Lexchin J, Wilkes MS, Beaulieu MD, Reynolds E, Sutherland J, Durrieu G.

J Gen Intern Med. 2013 Nov;28(11):1395. doi: 10.1007/s11606-013-2563-5. No abstract available.

46.

Too few, too weak: conflict of interest policies at Canadian medical schools.

Shnier A, Lexchin J, Mintzes B, Jutel A, Holloway K.

PLoS One. 2013 Jul 4;8(7):e68633. doi: 10.1371/journal.pone.0068633. Print 2013.

47.

Medication safety: opening up the black box.

Mintzes B.

BMJ Qual Saf. 2013 Sep;22(9):702-4. doi: 10.1136/bmjqs-2013-002238. Epub 2013 Jul 5. No abstract available.

PMID:
23832923
48.

Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States.

Mintzes B, Lexchin J, Sutherland JM, Beaulieu MD, Wilkes MS, Durrieu G, Reynolds E.

J Gen Intern Med. 2013 Oct;28(10):1368-75. doi: 10.1007/s11606-013-2411-7. Epub 2013 Apr 5.

49.

A systematic review of intravitreal bevacizumab for the treatment of diabetic macular edema.

Fortin P, Mintzes B, Innes M.

CADTH Technol Overv. 2013;3(1):e3203. Epub 2013 Feb 1. No abstract available.

50.

Review overemphasises benefits and downplays serious harms.

Musini V, Mintzes B, Tejani A, Wright JM.

BMJ. 2012 Sep 10;345:e5989; author reply e5990. doi: 10.1136/bmj.e5989. No abstract available.

PMID:
22963943

Supplemental Content

Loading ...
Support Center